Royalty Pharma (RPRX) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Portfolio performance and pipeline developments

• Consistent outperformance from key products like Tremfya and Trikafta, with significant growth potential remaining.

• Portfolio expanded by 8–10 new assets annually since IPO, now including over 30 new products.

• Recent investments include Voranigo for low-grade glioma and synthetic royalties in products like Rytelo, Niktimvo, and Yorvipath.

• Pipeline features near-term launches and longer-term opportunities, such as Lp(a) therapies and Sanofi's CD40 program.

• Aggregate royalties from new pipeline assets are estimated at $1.2 billion based on consensus.

Vertex royalty outlook and legal considerations

• Vertex royalties generated mid-$700 million last year, expected to grow to over $900 million under status quo.

• Legal dispute could reduce royalties to $600–$700 million if 50–75% of patients switch to a new triple therapy.

• Arbitration is the contractually mandated dispute resolution, considered more expedited than court proceedings.

• Visibility on arbitration outcome is expected to align with product launch timelines.

Market dynamics and product launches

• Lp(a) market expected to grow as awareness increases; Novartis' pelacarsen and Amgen's olpasiran are key near-term launches.

• Competition from oral therapies like Lilly's is anticipated, but market is not seen as winner-take-all.

• Cytokinetics' aficamten launch modeled with a REMS in place, with base case assuming Cytokinetics leads the launch.

• Recent launches include Rytelo for low-risk MDS and Niktimvo for chronic GVHD.